AChE/BChE-IN-35 

AChE/BChE-IN-35, Tacrine (HY-111338) derivative, is a brain-penetrant dual AChE/BChE inhibitor with an Electric Eel AChE IC₅₀ of 123.66 nM, human AChE IC₅₀ of 122.34 nM, and equine BChE IC₅₀ of 488.00 nM. AChE/BChE-IN-35 undergoes LAT1-mediated active transport across cell membranes. AChE/BChE-IN-35 exhibits enhanced brain exposure with slower brain tissue elimination. AChE/BChE-IN-35 can be used for the research of alzheimer's disease^[1].

AChE/BChE-IN-35 (Compound L3) (5 min) inhibits eeAChE, hAChE, and eqBChE with IC₅₀ values of 123.66 nM, 122.34 nM, and 488.00 nM, respectively^[1].
AChE/BChE-IN-35 (50-100 μM; 24 h) shows low cytotoxicity toward bEnd.3 cells, with viability remaining close to 80% after 24 h treatment at 100 μM^[1].
AChE/BChE-IN-35 (5 μg/mL; 30-300 min) crosses an in vitro bEnd.3 cell blood-brain barrier model with an apparent permeability coefficient of 11.25 × 10^-6 cm/s^[1].
AChE/BChE-IN-35 (4 h) is transported into U87 cells via LAT1, as shown by undetectable intracellular levels in the presence of an LAT1 competitive inhibitor^[1].
AChE/BChE-IN-35 (10-50 μM; 24 h) shows low cytotoxicity toward HBMEC, BV2, PC-12, SH-SY5Y, with viability remaining above 50% at tested concentrations after 24 h treatment^[1].
AChE/BChE-IN-35 (10-100 μM; 24 h) shows low hepatotoxicity in HepG2 and L02 cells, with viability remaining above 50% at tested concentrations after 24 h treatment[^1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

AChE/BChE-IN-35 (Compound L3) (10 mg/kg; i.p.; single dose) exhibits stronger blood-brain barrier permeability than Tacrine (HY-111338), with a brain-to-plasma AUC_0-t ratio of 0.68 and 21.3% higher total brain exposure^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

446.54

C₂₆H₃₀N₄O₃

OC([C@H](N)CC1=CC(C(NCCCNC2=C3C(C=CC=C3)=NC4=C2CCCC4)=O)=CC=C1)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gao Z, et al. A strategy for improving blood-brain barrier permeability of ChE inhibitors through blood-brain barrier (BBB) transporter. Eur J Med Chem. 2026;307:118687.